CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Income Statement
NASDAQ:CNTA - US1523091007 - ADR
17 USD
-0.01 (-0.06%)
17 USD
0 (0%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 | |||
| Operating Expenses | 222.00M | 201.00M | 178.00M | 212.26M | 153.63M | |||
| Research and Development | N/A | 150.24M | 124.41M | 155.08M | 95.66M | |||
| Selling, General, and Administrative Expenses | 51.00M | 51.00M | 54.00M | 55.20M | 42.89M | |||
| Operating Income | -207.00M | -201.00M | -171.00M | -212.26M | -153.63M | |||
| Interest Income/Expense | N/A | 3.93M | 570.00K | -7.03M | -1.17M | |||
| Other Income/Expense | 4.31M | -1.69M | -5.43M | 2.34M | -5.70M | |||
| Non Recurring Items | N/A | -34.00M | N/A | 0.00 | -220.45M | |||
| Income Before Taxes | -227.00M | -233.00M | -176.00M | -216.95M | -380.96M | |||
| Income Tax | 3.84M | 2.84M | -25.00M | -750.00K | 110.00K | |||
| Net Income | -230.00M | -236.00M | -151.00M | -216.21M | -381.07M | |||
| EBITDA | -206.10M | -200.06M | -170.19M | -212.13M | -153.60M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.79 | -2.06 | -1.57 | -2.31 | -5.07 | |||
| Non GAAP EPS | -1.53 | -1.73 | -1.57 | -2.31 | N/A | |||
| Statistics | ||||||||
| Profit Margin | -1533.33% | N/A | -2203.41% | N/A | N/A | |||
| Operating Profit Margin | -1380.00% | N/A | -2495.26% | N/A | N/A | |||
All data in USD